Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques.
Hum Vaccin Immunother
; 20(1): 2374147, 2024 Dec 31.
Article
en En
| MEDLINE
| ID: mdl-39090779
ABSTRACT
Entamoeba histolytica, the causative agent of amebiasis, is one of the top three parasitic causes of mortality worldwide. However, no vaccine exists against amebiasis. Using a lead candidate vaccine containing the LecA fragment of Gal-lectin and GLA-3M-052 liposome adjuvant, we immunized rhesus macaques via intranasal or intramuscular routes. The vaccine elicited high-avidity functional humoral responses as seen by the inhibition of amebic attachment to mammalian target cells by plasma and stool antibodies. Importantly, antigen-specific IFN-γ-secreting peripheral blood mononuclear cells (PBMCs) and IgG/IgA memory B cells (BMEM) were detected in immunized animals. Furthermore, antigen-specific antibody and cellular responses were maintained for at least 8 months after the final immunization as observed by robust LecA-specific BMEM as well as IFN-γ+ PBMC responses. Overall, both intranasal and intramuscular immunizations elicited a durable and functional response in systemic and mucosal compartments, which supports advancing the LecA+GLA-3M-052 liposome vaccine candidate to clinical testing.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Administración Intranasal
/
Anticuerpos Antiprotozoarios
/
Leucocitos Mononucleares
/
Vacunas Antiprotozoos
/
Interferón gamma
/
Entamoeba histolytica
/
Entamebiasis
/
Liposomas
/
Macaca mulatta
Límite:
Animals
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos